Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-SLE
NCT05843643Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 38
01
Overview
A Phase 3 trial of upadacitinib in systemic lupus erythematosus (SLE), sponsored by AbbVie Inc.. Started Jul 2023; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05843643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843643.